Alnylam Buoyed By Early Alzheimer’s Gene Silencing Success
Targets Early Disease-Causing Protein
Executive Summary
Alnylam has unveiled Phase I data showing its RNAi candidate can eliminate the amyloid precursor protein in the brain – opening the door to treating Alzheimer’s and many more CNS diseases.
You may also be interested in...
First Signs Of Efficacy From Biogen’s Tau-Targeting Antisense Drug
After showing an impressive 60% reduction in tau levels in the brain, Biogen’s Phase I study of BIIB080 has now demonstrated early signs of an impact on cognition and daily living for Alzheimer’s patients.
Lilly’s Donanemab Slows Cognitive Decline; FDA Filing Imminent
The company’s anti-amyloid antibody succeeded in Phase III with efficacy at least on par with Eisai/Biogen’s Leqembi, but with ARIA-related deaths unseen with the rival therapy.
Biogen Drug Sends Tau Into Reverse: An Alzheimer’s Breakthrough In The Making?
Phase I study and open-label extension results show a big drop in tau levels, which are more closely linked to Alzheimer’s symptoms than amyloid beta – setting up hopes of success in an ongoing Phase II study.